Paul has extensive experience of global sales, strategic marketing and business development. He was born in 1962 and was appointed as Aerocrine’s CEO in 2007. He was previously Senior Vice President of Commercial & Strategic Development, and a member of the corporate management of Biovitrum AB. He was also Executive Vice President of Global Strategic Marketing at Fresenius Kabi AB, which is part of the German Fresenius AG group, and was Head of Global Sales & Strategic Marketing at Pharmacia, as well as several international executive positions within the Unilever group in Europe.
He is the sole shareholder of Ytterby Holding AS.
Aerocrine shareholding: 20,650.

Mats Carlson COO, Director of Development and Technical Operations, M.Sc. (Eng.)

Mr Carlson was born in 1953 and has been a member of Aerocrine’s management since 1998. He has over 20 years’ product development and production experience in pharmaceuticals and medical technology. Mats is also a deputy Board member of RegMan AB. He was a Board member of the Swedish Industrial Design Foundation, SEDOC PM AB and the Karolinska Institute’s biotechnology Ph.D. program focusing on industry. His previous experience includes CEO of Pharmacia Chiron Partnership, a consultant for Wenell Management AB, Project Co-ordinator at Pharmacia and Project Manager at Siemens-Elema in product development for intensive care.
Aerocrine shareholding: 3,000 and warrants corresponding to 160,000 shares.

Michael Colérus Chief Financial Officer, B.Sc. (Econ.)

Michael Colérus has a professional background in Pharmacia & Upjohn where he was Business Controller for several business areas. Michael was born in 1962, and has been Aerocrine’s CFO since 1999.
Aerocrine shareholding: 5,300 and warrants corresponding to 30,000 shares.

Lena Kajland-Wilén Marketing Director, M.Sc. (Eng)

Lena Kajland-Wilén has broad pharmaceuticals industry experience. Lena was born in 1960 and has been Aerocrine’s Marketing Director since 2000; 15 years’ professional experience of global strategic marketing at Pharmacia & Upjohn, holding various positions in the Ophthalmology unit, including Marketing Manager for Viscoelastics, Marketing Director for Glaucoma and Business Manager for a new macular degeneration drug.
Aerocrine shareholding: warrants corresponding to 42,000 shares.

Johanna Karling  QA & Regulatory Affairs Director, M.Sc. (Eng)

Johanna previously held various positions within Pharmacia & Upjohn, in segments including Quality Assurance and Regulatory Affairs for Peptide Hormones between 1992 and 1994, and was a Project Manager in Global Supply from 1996 to 1999. She was born in 1963 and became Aerocrine’s QA Director in 1999.
Aerocrine shareholding: warrants corresponding to 30,000 shares.

Anna Malm Bernsten Vice President Global Sales and M.Sc. (Eng)

Anna has broad experience of senior executive positions in the life science industry. Anna was born in 1961 and took up her position with Aerocrine in 2007. She is a Board member of Medivir AB, AB Fagerhult, DiaGenic ASA and Artimplant AB. She has been a member of the management teams of Medivir AB and Assa Abloy AB, and held senior executive positions with Pharmacia & Upjohn. She was previously CEO of Carmeda AB and Cortree AB.
Aerocrine shareholding: 0

Kjell Alving Director of Scientific & Medical Affairs

Kjell Alving is the Director of Scientific & Medical Affairs and also co-founder of Aerocrine AB. Kjell is a Professor of Respiratory Pharmacology. He was born in 1959 and took up his position in Aerocrine’s management team in 2007. He joined Aerocrine from the Karolinska Institute, where he has been active in preclinical and clinical research for more than 20 years. His research included the discovery that asthmatics have increased NO levels in exhaled air. Kjell is a Board member of Alving & Ersson AB, and was previously a Board member of Nitricare AB. Kjell previously conducted allergy research in the former Pharmacia Diagnostics AB.
Aerocrine shareholding: 139,440 and warrants corresponding to 70,000 shares.